Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：2

作者：

Spencer, Andrew ^{[1
]}

Iversen, Katrine Fladeland ^{[2
]}

Dhakal, Binod ^{[3
]}

Creignou, Maria ^{[4
]}

Chen, Jenny ^{[5
]}

Hiemstra, Ida H. ^{[6
]}

Bosgra, Sieto ^{[6
]}

Badani, Avani ^{[5
]}

Breij, Esther C. W. ^{[6
]}

Brady, Lauren K. ^{[5
]}

Sasser, A. Kate ^{[5
]}

Malmberg, Anders ^{[7
]}

Gregersen, Henrik ^{[8
]}

Hansson, Markus ^{[9
]}

Broijl, Annemiek ^{[10
]}

Mateos, Maria-Victoria ^{[11
]}

Plesner, Torben ^{[2
]}

机构：

[1] Alfred Hosp, Melbourne, Vic, Australia

[2] Vejle Hosp, Vejle, Denmark

[3] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA

[4] Karolinska Univ Hosp, Dept Hematol, Huddinge, Sweden

[5] Genmab, Princeton, NJ USA

[6] Genmab, Utrecht, Netherlands

[7] Genmab, Copenhagen, Denmark

[8] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark

[9] Aalborg Univ Hosp, Aalborg, Denmark

[10] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[11] USAL CSIC, Hosp Univ Salamanca, IBSAL, IBMCC, Salamanca, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7320 / 7321

页数：2

共 50 条

[21] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Chari, Ajai
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Liu, Kevin
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2017, 130
[22] A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Hansson, Markus
Gimsing, Peter
Badros, Ashraf
Niskanen, Titti Martinsson
Nahi, Hareth
Offner, Fritz
Salomo, Morten
Sonesson, Elisabeth
Mau-Sorensen, Morten
Stenberg, Yvonne
Sundberg, Annika
Teige, Ingrid
Van Droogenbroeck, Jan
Wichert, Stina
Zangari, Maurizio
Frendeus, Bjorn
Korsgren, Magnus
Poelman, Martine
Tricot, Guido
CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2730 - 2736
[23] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
Iida, Shinsuke
Sunami, Kazutaka
Minami, Hironobu
Hatake, Kiyohiko
Sekiguchi, Risa
Natsume, Kazuto
Ishikawa, Norifumi
Rinne, Mikael
Taniwaki, Masafumi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 797 - 806
[24] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
Sugiura, Isamu
Terabe, Satomi
Kinoshita, Tomohiro
Yamamoto, Kazuhito
Sawa, Masashi
Ozawa, Yukiyasu
Atsuta, Yoshiko
Suzuki, Ritsuro
Shimizu, Kazuyuki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (04) : 434 - 440
[25] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
Isamu Sugiura
Satomi Terabe
Tomohiro Kinoshita
Kazuhito Yamamoto
Masashi Sawa
Yukiyasu Ozawa
Yoshiko Atsuta
Ritsuro Suzuki
Kazuyuki Shimizu
International Journal of Hematology, 2015, 102 : 434 - 440
[26] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
Shinsuke Iida
Kazutaka Sunami
Hironobu Minami
Kiyohiko Hatake
Risa Sekiguchi
Kazuto Natsume
Norifumi Ishikawa
Mikael Rinne
Masafumi Taniwaki
International Journal of Hematology, 2021, 113 : 797 - 806
[27] Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Yee, Andrew
Laubach, Jacob
Nooka, Ajay
O'Donnell, Elizabeth
Harrington, Cynthia
Agyemang, Emerentia
Burke, Jill
Gammon, Marilyn
Lively, Kathleen
Packer, Lisette
Bishop, James
Bernstein, Zachary
Lyons, Rebecca
Wright, Alexandra
McVey, Cailin
Richardson, Paul
Raje, Noopur
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S58 - S59
[28] Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
Kumar, Shaji
Bensinger, William I.
Reeder, Craig B.
Zimmerman, Todd M.
Berenson, James R.
Berg, Deborah
Liu, Guohui
Gupta, Neeraj
Di Bacco, Alessandra
Hui, Ai-Min
Niesvizky, Ruben
BLOOD, 2011, 118 (21) : 371 - 372
[29] Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
Berenson, James R.
Klein, Leonard M.
Rifkin, Robert M.
Patel, Priti
Dixon, Sandra
Ou, Ying
Cartmell, Alan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
Hongmei Jing
Li Yang
Junyuan Qi
Lugui Qiu
Chengcheng Fu
Junmin Li
Min Yang
Ming Qi
Ni Fan
Jia Ji
Jiajia Lu
Yunan Li
Jie Jin
Annals of Hematology, 2022, 101 : 2679 - 2690

← 1 2 3 4 5 →